BridgeBio Pharma, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 13 rows, 13 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-07-01: Reporting owner KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P.; Form 4; Security Series B Preferred Units; Transaction C Conversion of derivative security.
- 2019-07-01: Reporting owner KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P.; Form 4; Security Series C Preferred Units; Transaction C Conversion of derivative security.
- 2019-07-01: Reporting owner KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P.; Form 4; Security Series D Preferred Units; Transaction C Conversion of derivative security.
- 2019-06-27: Reporting owner Viking Long Fund Master Ltd. | Ott David C. | HALVORSEN OLE ANDREAS | Viking Global Equities Master Ltd. | VIKING GLOBAL PERFORMANCE LLC | Viking Long Fund GP LLC | Shabet Rose Sharon; Form 4; Security Series C Preferred Units; Transaction C Conversion of derivative security.
BBIO insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-07-01 | KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series B Preferred Units Derivative · Indirect · See footnotes | C Conversion of derivative security | −81,022,727 0 owned after | no price filed | $27.37 | 2019-07-03 |
| 2019-07-01 | KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Units Derivative · Indirect · See footnotes | C Conversion of derivative security | −36,246,893 0 owned after | no price filed | $27.37 | 2019-07-03 |
| 2019-07-01 | KKR & Co. Inc. | KKR Group Holdings Corp. | KKR Management LLC | KKR Management Holdings Corp | ROBERTS GEORGE R | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR Genetic Disorder L.P. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series D Preferred Units Derivative · Indirect · See footnotes | C Conversion of derivative security | −50,446,451 0 owned after | no price filed | $27.37 | 2019-07-03 |
| 2019-06-27 | Viking Long Fund Master Ltd. | Ott David C. | HALVORSEN OLE ANDREAS | Viking Global Equities Master Ltd. | VIKING GLOBAL PERFORMANCE LLC | Viking Long Fund GP LLC | Shabet Rose Sharon 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Units Derivative · Indirect · See Explanation of Responses | C Conversion of derivative security | −51,781,276 0 owned after | no price filed | $27.55 | 2019-06-28 |
| 2019-06-27 | Viking Long Fund Master Ltd. | Ott David C. | HALVORSEN OLE ANDREAS | Viking Global Equities Master Ltd. | VIKING GLOBAL PERFORMANCE LLC | Viking Long Fund GP LLC | Shabet Rose Sharon 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series D Preferred Units Derivative · Indirect · See Explanation of Responses | C Conversion of derivative security | −50,446,451 0 owned after | no price filed | $27.55 | 2019-06-28 |
| 2019-06-27 | Shabet Rose Sharon | Ott David C. | HALVORSEN OLE ANDREAS | Viking Global Opportunities GP LLC | VIKING GLOBAL INVESTORS LP | Viking Global Opportunities Portfolio GP LLC | Viking Global Opportunities Illiquid Investments Sub-Master LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series C Preferred Units Derivative · Indirect · See Explanation of Responses | C Conversion of derivative security | −51,781,276 0 owned after | no price filed | $27.55 | 2019-06-28 |
| 2019-06-27 | Shabet Rose Sharon | Ott David C. | HALVORSEN OLE ANDREAS | Viking Global Opportunities GP LLC | VIKING GLOBAL INVESTORS LP | Viking Global Opportunities Portfolio GP LLC | Viking Global Opportunities Illiquid Investments Sub-Master LP 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 4 | Series D Preferred Units Derivative · Indirect · See Explanation of Responses | C Conversion of derivative security | −50,446,451 0 owned after | no price filed | $27.55 | 2019-06-28 |
| 2019-06-27 holding as of filing | Viking Global Opportunities Portfolio GP LLC | Viking Global Opportunities GP LLC | VIKING GLOBAL INVESTORS LP | Shabet Rose Sharon | HALVORSEN OLE ANDREAS | Viking Global Opportunities Illiquid Investments Sub-Master LP | Ott David C. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Units Derivative · Indirect · See Explanation of Responses | Holding | no price filed | 2019-06-27 | ||
| 2019-06-27 holding as of filing | Viking Global Opportunities Portfolio GP LLC | Viking Global Opportunities GP LLC | VIKING GLOBAL INVESTORS LP | Shabet Rose Sharon | HALVORSEN OLE ANDREAS | Viking Global Opportunities Illiquid Investments Sub-Master LP | Ott David C. 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Units Derivative · Indirect · See Explanation of Responses | Holding | no price filed | 2019-06-27 | ||
| 2019-06-27 holding as of filing | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR & Co. Inc. | ROBERTS GEORGE R | KKR Genetic Disorder L.P. | KKR Management LLC | KKR Group Holdings Corp. | KKR Management Holdings Corp 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series B Preferred Units Derivative · Indirect · See Footnotes | Holding | no price filed | 2019-06-27 | ||
| 2019-06-27 holding as of filing | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR & Co. Inc. | ROBERTS GEORGE R | KKR Genetic Disorder L.P. | KKR Management LLC | KKR Group Holdings Corp. | KKR Management Holdings Corp 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series C Preferred Units Derivative · Indirect · See Footnotes | Holding | no price filed | 2019-06-27 | ||
| 2019-06-27 holding as of filing | KRAVIS HENRY R | KKR Genetic Disorder GP LLC | KKR Management Holdings L.P. | KKR & Co. Inc. | ROBERTS GEORGE R | KKR Genetic Disorder L.P. | KKR Management LLC | KKR Group Holdings Corp. | KKR Management Holdings Corp 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 3 | Series D Preferred Units Derivative · Indirect · See Footnotes | Holding | no price filed | 2019-06-27 | ||
| 2019-06-27 holding as of filing | Kumar Neil Director, Officer (See Remarks) | 3 | Series B Preferred Units Derivative · Indirect · (m) | Holding | no price filed | 2019-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |